Abstract:Peptides are ideally suited to mimic natural ligands and thereby function in an antagonistic or agonistic way. Furthermore they are able to physiologically disrupt functional complexes due to their small size and specific binding properties. Proteins form homo- or heteromeric (macro)molecular complexes and intricate networks by interacting with small molecules, peptides, nucleic acids or other proteins. On average, five interaction partners have been estimated for any given cellular protein, illustrating the complexity of the formed 'interactomes' and the impact of their investigation. Many protein-protein interactions are mediated by hot-spots, which comprise only a small part of the large binding interface but account for 80% of the binding energy. Thus, these hot spots provide an 'Achilles heel' for pharmaceutical interventions aiming at the disruption of functional protein-protein complexes. Methods to select peptides for defined target structures include display technologies on phages, ribosomes or yeast, and the yeast-two-hybrid system. Once selected, these peptides can be optimized for their binding affinity using peptide arrays. Stabilization of biologically unstable peptides is achieved by the introduction of non-natural amino acids to form so-called peptidomimetics that are resistant to cellular proteases. Moreover, lipocalins and peptide aptamers represent scaffolded binding structures with unique binding characteristics and enhanced stability. In case of extracellular targets, like cell surface receptors or pathogens in patients` plasma, peptide inhibitors have direct access. Addressing intracellular targets with peptides is more difficult since short hydrophilic peptides generally do not cross plasma membranes on their own. However, intracellular uptake of peptides can be achieved by coupling to carrier systems like liposomes or nanoparticles or upon fusion to a protein transduction domain. Alternatively, peptides may be expressed within cells after transduction with viral vectors in a gene therapy setting. This review will summarize the broad potential of peptides as drugs, with special emphasis on peptides which inhibit protein-protein interactions.

Peptide-Based Inhibitors of the Induced Signaling Protein Interactions: Current State and Prospects

Peptide-based inhibitors of protein–protein interactions: biophysical, structural and cellular consequences of introducing a constraint

Peptides as drugs: from screening to application

Current State of Imaging Protein-Protein Interactions In Vivo with Genetically Encoded Reporters

Use of phosphotyrosine-containing peptides to target SH2 domains: Antagonist peptides of the Crk/CrkL-p130Cas axis

Disrupting Protein Complexes Using Tat-Tagged Peptide Mimics

Beyond Transduction: Anti-Inflammatory Effects of Cell Penetrating Peptides

Tuning Insulin Receptor Signaling Using De Novo Designed Agonists

Peptide therapeutics: Targeting the undruggable space

Rational Design of Peptide-Based Inhibitors Disrupting Protein-Protein Interactions

Efficient PROTAC-ing: combinational use of PROTACs with signaling pathway inhibitors

Engineering conditional protein-protein interactions for dynamic cellular control

Recent progress in the development of Toll-like receptor (TLR) antagonists

A Comprehensive Review on Current Advances in Peptide Drug Development and Design

Therapeutic design of peptide modulators of protein-protein interactions in membranes

Therapeutic effects of cell-permeant peptides that activate G proteins downstream of growth factors

Small molecules, big targets: drug discovery faces the protein–protein interaction challenge

Signal Transduction in Artificial Cells

In-silico assessment of novel peptidomimetics inhibitor targeting STAT3 and STAT4 N-terminal domain dimerization: A comprehensive study using molecular docking, molecular dynamics simulation, and binding free energy analysis

Controlling the Subcellular Localization of Signaling Proteins Using Chemically Induced Dimerization and Optogenetics

Combinatorial proteomic analysis of intercellular signaling applied to the CD28 T-cell costimulatory receptor